[Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)].

Scholz, Godehard Albert; Möller, Burkhard (2017). [Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)]. Zeitschrift für Rheumatologie, 76(1), pp. 21-26. Springer-Medizin-Verlag 10.1007/s00393-016-0242-8

Preview

Text 10.1007_s00393-016-0242-8.pdf - Published Version Available under License Publisher holds Copyright. Download (342kB) | Preview

BACKGROUND

Immunomodulatory long-term treatment has also become the standard treatment for spondyloarthritides (SpA), including psoriatic arthritis (PsA); however, uncertainty exists about dose reduction or termination of treatment after remission or low disease activity.

OBJECTIVE

When is it possible to reduce medication or terminate treatment for SpA?

MATERIAL AND METHODS

An extensive non-systematic literature search was performed focusing on practice guidelines, systematic meta-analyses and clinical trials on medicinal long-term treatment and voluntary medication reduction in axial and peripheral SpA, including PsA.

RESULTS

The chances of drug-free remission after treatment with biologics for axial SpA and in PsA are low; however, in remission or a state of low disease activity reduction of the cumulative dosage of biologics can be successful in 53-100% of cases without a significant increase in disease activity. The current state and duration of remission, with or without comedication with nonsteroidal anti-inflammatory drugs (NSAID), extra-articular disease manifestations and the results of previous treatment attempts have to be carefully taken into consideration before elective dose reduction.

CONCLUSION

Reduction of long-term treatment is an individualized decision made jointly by patients and physicians. The risk of flares and especially of extra-articular disease manifestations needs to be weighed against the possible advantages of reduced medication. Maintainenance of mediction-free disease remission is too rare in SpA or PsA patients carefully selected for biologics treatment, to allow a later voluntary termination of therapy, without at least a prior cautious attempt at dose reduction.

Interest & Impact

Downloads

68 since deposited on 19 Jul 2017
47 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item